logo-loader
viewCynata Therapeutics Ltd

Cynata Therapeutics welcomes UK Regulatory Authority approval of Phase 2 clinical trial in critical limb ischaemia

In a preclinical study in a mouse model of CLI, treatment with Cymerus MSCs led to significantly higher blood flow in the ischaemic limb and protection against muscle damage, fibrosis and limb loss.

Cynata Therapeutics Ltd - Cynata Therapeutics welcomes UK Regulatory Authority approval of Phase 2 clinical trial in Critical Limb Ischaemia
Treatment of CLI typically involves surgery such as stents, angioplasty and vascular grafts

Cynata Therapeutics Limited (ASX:CYP) welcomes approval from the UK Medicines and Healthcare products Regulatory Agency (MHRA) to proceed with its Phase 2 clinical trial of the Cymerus™ mesenchymal stem cell (MSC) product CYP-002 in patients with critical limb ischaemia (CLI).

CLI is an advanced stage of peripheral artery disease (PAD), a narrowing of arteries in the limbs which is a major risk factor for cardiovascular events such as heart attack.

Cynata chief operating officer Dr Kilian Kelly said approval of the Phase 2 clinical trial was a major step for treatment of the condition.

He said: “The approval of this Phase 2 clinical trial by the MHRA is a major advancement for the development of Cymerus MSCs.

“We look forward to working with our contract research organisation and clinical investigators to evaluate CYP-002 in this devastating condition, for which there remains an enormous unmet need. 

“The approval also confirms the successful implementation of the company’s strategy to use the positive Phase 1 trial of Cymerus MSCs in graft versus host disease to support direct progression from preclinical to Phase 2 clinical studies for CLI and multiple other indications.”

Cynata anticipates conducting the clinical trial at multiple centres in the UK and Australia.

CLI prevalence increasing

The risk of PAD is increased in patients with diabetes, obesity, high blood pressure and in people who smoke and can often result in amputation of the affected limb.

Outcomes in CLI patients are typically poor and with CLI prevalence estimated to be approximately 2 million patients in the United States alone and likely to rise, as such, the value of the global CLI treatment market has been forecasted to reach US$5.4 billion by 2025.

Cynata is working to develop better treatment options to meet the growing commercial need.

Economic manufacture of products

Cymerus overcomes the challenges of other production methods by using induced pluripotent stem cells (iPSCs) and a precursor cell known as mesenchymoangioblast (MCA) to achieve economic manufacture of cell therapy products, including mesenchymal stem cells (MSCs), at commercial scale without the limitation of multiple donors.

In the Phase 1 trial, Cynata’s CYP-001 product met all clinical endpoints and demonstrated positive safety and efficacy data for the treatment of steroid-resistant acute graft-versus-host disease (GvHD).

The company plans to advance its Cymerus™ MSCs into Phase 2 trials for GvHD, critical limb ischemia and osteoarthritis.

The technology has also proved efficient in preclinical models of asthma, diabetic wounds, heart attack and cytokine release syndrome - a life-threatening condition stemming from cancer immunotherapy.

Quick facts: Cynata Therapeutics Ltd

Price: 0.63 AUD

ASX:CYP
Market: ASX
Market Cap: $73.79 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Cynata Therapeutics Ltd named herein, including the promotion by the Company of Cynata Therapeutics Ltd in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Cynata Therapeutics announces trial in critical COVID-19 patients using...

Cynata Therapeutics (ASX: CYP) COO Kilian Kelly joined Steve Darling from Proactive Vancouver with news the unique stem cell biotech company is beginning a trial in patients suffering from the effects of the coronavirus. Kelly telling Proactive how their technology works and why this...

on 15/5/20

3 min read